News
The drugmaker shed billions of dollars in value after it told investors that widening Journavx’s approval to chronic pain ...
Franklin Templeton shares Q2 2025 results for ClearBridge All Cap Growth Portfolios: tech wins offset health care drag. See ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback